Spinal Muscular Atrophy Type 2 Latest Advances

Hirayama disease: an uncommon cause of motor neuron disease.

Journal: Arquivos de neuro-psiquiatria

Published: March 19, 2026

Impairment of lip and tongue strength in symptomatic SMA1 patients: Results from a 4-center prospective study using the IOPI.

Journal: Journal of neuromuscular diseases

Published: March 14, 2026

Risdiplam therapy in adult patients with Spinal muscular Atrophy (SMA). A 24-month-real-world experience at a single muscular centre.

Journal: Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology

Published: March 12, 2026

Learning outcomes of infants and young children with spinal muscular atrophy type I provided with modified-electric-toy-cars in their natural environment.

Journal: Assistive technology : the official journal of RESNA

Published: March 10, 2026

When Neuromuscular Weakness Is Not Chemotherapy‑Related: Spinal Muscular Atrophy Type II Diagnosed After Acute Lymphoblastic Leukemia Onset in a 1-Year-Old Child: A Case Report and Review of the Literature.

Journal: Pediatric blood & cancer

Published: March 05, 2026

Relationships between home and community participation, social-cognitive skills, and powered mobility learning in children with SMA type I: A randomized, waiting-list controlled trial.

Journal: Assistive technology : the official journal of RESNA

Published: February 17, 2026

Characteristics of early-onset, rapidly progressive scoliosis in spinal muscular atrophy type I treated with disease-modifying therapy -a multicenter retrospective study conducted in Japan.

Journal: Journal of neuromuscular diseases

Published: January 07, 2026

PDXK-Related Neuropathy: A Case With a Novel Splice-Altering Missense Variant and Literature Review.

Journal: Molecular genetics & genomic medicine

Published: January 01, 2026

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24-Month Follow-Up From the Italian Registry.

Journal: Annals of clinical and translational neurology

Published: December 29, 2025

Cognitive and neurodevelopmental disorders in spinal muscular atrophy type I at the time of disease-modifying therapies.

Journal: Developmental medicine and child neurology

Published: December 23, 2025

Body Weight and Range of Motion as Predictors of Trunk Asymmetry in Children With Spinal Muscular Atrophy: A Prospective Functional Assessment.

Journal: Medical science monitor : international medical journal of experimental and clinical research

Published: December 23, 2025

Disparities in Spinal Muscular Atrophy-Related Mortality in the United States, 2018-2023.

Journal: NeuroSci

Published: December 03, 2025

Spinal Muscular Atrophy Type 2 Latest Advances

Find the Latest Research About Spinal Muscular Atrophy Type 2

Hirayama disease: an uncommon cause of motor neuron disease.

Hirayama disease: an uncommon cause of motor neuron disease.

Impairment of lip and tongue strength in symptomatic SMA1 patients: Results from a 4-center prospective study using the IOPI.

Impairment of lip and tongue strength in symptomatic SMA1 patients: Results from a 4-center prospective study using the IOPI.

Risdiplam therapy in adult patients with Spinal muscular Atrophy (SMA). A 24-month-real-world experience at a single muscular centre.

Risdiplam therapy in adult patients with Spinal muscular Atrophy (SMA). A 24-month-real-world experience at a single muscular centre.

Learning outcomes of infants and young children with spinal muscular atrophy type I provided with modified-electric-toy-cars in their natural environment.

Learning outcomes of infants and young children with spinal muscular atrophy type I provided with modified-electric-toy-cars in their natural environment.

When Neuromuscular Weakness Is Not Chemotherapy‑Related: Spinal Muscular Atrophy Type II Diagnosed After Acute Lymphoblastic Leukemia Onset in a 1-Year-Old Child: A Case Report and Review of the Literature.

When Neuromuscular Weakness Is Not Chemotherapy‑Related: Spinal Muscular Atrophy Type II Diagnosed After Acute Lymphoblastic Leukemia Onset in a 1-Year-Old Child: A Case Report and Review of the Literature.

Relationships between home and community participation, social-cognitive skills, and powered mobility learning in children with SMA type I: A randomized, waiting-list controlled trial.

Relationships between home and community participation, social-cognitive skills, and powered mobility learning in children with SMA type I: A randomized, waiting-list controlled trial.

Characteristics of early-onset, rapidly progressive scoliosis in spinal muscular atrophy type I treated with disease-modifying therapy -a multicenter retrospective study conducted in Japan.

Characteristics of early-onset, rapidly progressive scoliosis in spinal muscular atrophy type I treated with disease-modifying therapy -a multicenter retrospective study conducted in Japan.

PDXK-Related Neuropathy: A Case With a Novel Splice-Altering Missense Variant and Literature Review.

PDXK-Related Neuropathy: A Case With a Novel Splice-Altering Missense Variant and Literature Review.

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24-Month Follow-Up From the Italian Registry.

Onasemnogene Abeparvovec in Type I Spinal Muscular Atrophy: 24-Month Follow-Up From the Italian Registry.

Cognitive and neurodevelopmental disorders in spinal muscular atrophy type I at the time of disease-modifying therapies.

Cognitive and neurodevelopmental disorders in spinal muscular atrophy type I at the time of disease-modifying therapies.

Body Weight and Range of Motion as Predictors of Trunk Asymmetry in Children With Spinal Muscular Atrophy: A Prospective Functional Assessment.

Body Weight and Range of Motion as Predictors of Trunk Asymmetry in Children With Spinal Muscular Atrophy: A Prospective Functional Assessment.

Disparities in Spinal Muscular Atrophy-Related Mortality in the United States, 2018-2023.

Disparities in Spinal Muscular Atrophy-Related Mortality in the United States, 2018-2023.